Bristol-Myers Squibb Company
Business Model Analysis
How Bristol-Myers Squibb Makes Money
Annual Revenue: $48.2B
Bristol-Myers Squibb generates revenue primarily through Pharmaceuticals and Biotechnology, with roughly $48.2B in annual revenue.
Core Growth Engine: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7...
Revenue Model & Pricing
BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.
Core Revenue Streams
Growth Portfolio
~55%$26.4 billion in 2025, up 17%: Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Sotyktu, Cobenfy, Krazati and other newer brands. It grew another 15% to $7.56 billion in the second quarter of 2026.
Legacy Portfolio
~45%$21.8 billion in 2025: Eliquis ($14.4 billion), Revlimid ($3.0 billion), Pomalyst/Imnovid ($2.7 billion), Sprycel, Abraxane and other mature brands facing generic competition. Legacy revenue fell 4% in the second quarter of 2026.
Growth Strategy
BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.
How Bristol-Myers Squibb Makes Money: FAQ
How does Bristol-Myers Squibb generate revenue as a global biopharmaceutical leader?
BMS generates revenue through the discovery, clinical development, patenting, manufacturing, and global commercial distribution of prescription biopharmaceutical biologics and specialty small-molecule medicines, selling through pharmaceutical wholesalers, hospitals, and specialty pharmacies.
What are BMS's core therapeutic franchises?
BMS organizes its commercial business across four primary therapeutic pillars: Oncology & Hematology (Opdivo, Yervoy, Revlimid, Pomalyst, Reblozyl), Cardiovascular (Eliquis, Camzyos), Immunology (Orencia, Sotyktu, Zeposia), and Neuroscience (Cobenfy).
How is the commercial collaboration with Pfizer structured for Eliquis?
Bristol-Myers Squibb and Pfizer share global development costs and split operating profits and losses equally (50:50) from commercial sales of Eliquis, with BMS reporting net product sales in the US and major international markets.
What is BMS's 'Growth Portfolio' vs 'Legacy Portfolio' revenue strategy?
BMS segments its portfolio into mature legacy medicines facing generic erosion (Revlimid, Pomalyst, Sprycel) and a high-margin 'Growth Portfolio' of newly launched blockbusters (Opdualag, Camzyos, Sotyktu, Breyanzi, Reblozyl, Cobenfy) targeted to drive long-term revenue growth.
How does BMS manufacture advanced CAR-T autologous cell therapies?
For CAR-T therapies (Breyanzi and Abecma), BMS operates specialized cell therapy manufacturing centers in New Jersey, Massachusetts, and Washington, harvesting a patient's own T-cells, genetically re-engineering them with chimeric antigen receptors (CAR), and re-infusing them to destroy blood cancers.
How does BMS protect its innovative medicines against patent cliffs?
BMS protects its drug pipeline through comprehensive composition-of-matter patents, regulatory orphan drug exclusivities, developing next-generation subcutaneous formulations (subcutaneous Opdivo), and executing strategic multi-billion-dollar M&A to acquire late-stage clinical assets.
What role do biomanufacturing facilities in Ireland and the US play for BMS?
BMS operates high-quality biologics manufacturing facilities in Cruiserath (Dublin, Ireland), Devens (Massachusetts), and Syracuse (New York), utilizing industrial multi-thousand-liter bioreactors to manufacture high-yield therapeutic monoclonal antibodies.
How does BMS allocate capital toward pharmaceutical Research & Development?
BMS routinely reinvests approximately 20% of its annual revenues into R&D (over $9 billion annually), funding clinical trials across oncology checkpoints, antibody-drug conjugates (ADCs), targeted protein degradation, and radiopharmaceuticals.
How does Bristol-Myers Squibb make money?
BMS generates massive revenue by heavily investing in R&D and executing massive acquisitions to secure the patents for highly specialized, premium-priced biologics, specifically in cancer and immunology.
Related Companies
Compare Bristol-Myers Squibb Company With Competitors
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Novo Nordisk A/S
Eli Lilly and Company
Novartis AG
Bausch Health Companies Inc.
Pfizer
Merck
Explore Bristol-Myers Squibb
Core profile pages, founders and related research hubs for this company.